期刊文献+

盐霉素增强吉非替尼诱导人肺腺癌细胞株PC9凋亡作用 被引量:2

The promotion of salinomycin on the apoptosis of human lung adenocarcinoma cell line PC9 induced by gefitinib
下载PDF
导出
摘要 目的:探讨盐霉素联合吉非替尼诱导人肺腺癌细胞株PC9凋亡作用。方法:MTT法检测细胞增殖活性;流式细胞仪检测细胞凋亡及线粒体膜电位(MMP);比色法检测Caspase-3、8和9酶活性;Westernblot分析细胞色素C、bcl-2、p-EGFR、p-Akt和p-ERK蛋白水平。结果:盐霉素与吉非替尼单用均出现不同程度的细胞增殖抑制作用和诱导细胞凋亡作用;而两者合用则能更显著地抑制细胞增殖,且细胞凋亡显著增加(P<0.05)。盐霉素单独作用,细胞MMP显著下降,细胞内活性氧和Ca2+在短期显著升高,胞浆细胞色素C、Caspase-3、8和9酶活性均显著增加;吉非替尼单用则抑制p-EGFR、p-Akt和p-ERK蛋白表达,而对胞浆细胞色素C、Caspase-3、8和9酶活性影响较少。Western印迹检测发现,联合用药组的Bcl-2、p-EGFR、p-Akt和p-ERK蛋白表达量明显减少。结论:盐霉素与吉非替尼联用具有较好的协同作用,提高PC9细胞对吉非替尼的敏感性。 Objective To investigate the effects of salinomycin combined with gefitinib on the apoptosis of human non-small cell lung cancer cell line PC9.Methods The growth of PC9 cells was tested by MTT,cell apoptosis and mitochondria membrane potential(MMP) were measured by flow cytometry,the activities of caspase-3,8,and 9 were detected by colorimetry,and the levels of cytochrome C,bcl-2,p-EGFR,p-Akt,and p-ERK were analyzed by Western blot.Results Salinomycin or gefitinib alone could inhibit the growth and induce the apoptosis of PC9 cells in a dose-dependent manner;when they were combined with each other,these effects were more obvious(P 0.05).Salinomycin alone could significantly reduce the MMP and increase the levels of intracellular reactive oxygen species(ROS),cytoplasmic cytochrome C,and cytosolic Ca2+,and the activities of caspase-3,8,and 9.Gefitinib alone could inhibit the expressions of p-EGFR,p-Akt,and p-ERK protein,and less affect the level of cytochrome C and the activities of caspase-3,8 and 9.Western blotting showed that the expressions of Bcl-2,p-EGFR,p-Akt,and p-ERK protein were significantly decreased in combined group.Conclusion There exist synergism between salinomycin and gefitinib,and salinomycin can increase the sensitivity of PC9 cells to gefitinib.
出处 《实用医学杂志》 CAS 北大核心 2012年第14期2312-2315,共4页 The Journal of Practical Medicine
基金 国家自然科学基金资助(编号:30670902)
关键词 细胞凋亡 盐霉素 肺腺癌细胞 吉非替尼 Apoptosis Salinomycin Gefitinib Lung adenocarcinoma
  • 相关文献

参考文献7

  • 1Goldstraw P, Ball D, Jett J R, et al. Non-small-cell lung cancer [ J ]. Lancet, 2011,378 (9804) : 1727-1740.
  • 2Stella G M, Luisetti M, Inghilleri S, et al. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies [J]. Respir Med, 2012,106(2) : 173-183.
  • 3黄雪琴,张为民,谢波,郑积华,徐志勇,王仙赐,林金容.Gefitinib治疗晚期耐药非小细胞肺癌的疗效及不良反应[J].实用医学杂志,2011,27(14):2639-2641. 被引量:4
  • 4罗琼.沙利度胺联合GP方案治疗晚期非小细胞肺癌[J].实用医学杂志,2011,27(6):1080-1082. 被引量:9
  • 5Zhi Q M, Chen X H, Ji J, et al. Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer [J]. Biomed Pharmacother, 2011,65 ( 7 ) : 509-515.
  • 6Ketola K, Hilvo M, Hytotylaiinen T, et al. Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress[J]. Br J Cancer, 2012,106 ( 1 ) : 99-106.
  • 7Kim K Y, Yu S N, Lee S Y, et al. Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization [J]. Biochem Biophys Res Commun, 2011,413 (1):80-86.

二级参考文献12

  • 1Hsueh-Erh Chiou,Tsang-En Wang,Ying-Yue Wang,Hui-Wen Liu.Efficacy and safety of thalidomide in patients with hepatocellular carcinoma[J].World Journal of Gastroenterology,2006,12(43):6955-6960. 被引量:21
  • 2Goffin J, Laechetti C, Ellis P M, et al. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review [J].J Thorac Oncol,2010,5(2): 260-274.
  • 3Lee H Y, Anh M J, Park Y H, et al. Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, muhicenter trial[J].Lung Cancer, 2009,66 (3) : 338-343.
  • 4Sandier A B, Gray R, Perry M C, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer [J]. N Engl J Med, 2006,355 (24) : 2542-2550.
  • 5Anderson N G, Ahmad T, Chan K, et al. ZD1839(IRESSA), a novel epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor,potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression [J]. lnt J Cancer. 2001.94(6) :774-782.
  • 6Fukuoka M, Yano S, Giaccone G, et al. Multi-institutionalrandomized phase Ⅱ trial of Gefinitibfor previously treated patients with advanced non-smalll cell lung cancer(the IDEAL1 Trail) [J]. J Clin 0ncol,2003,21(12):2237-2246.
  • 7Kris M G, Natale R S, Herbst R S, et al. Efficacy of Gefinitib, an inhibitor of the epidermal growth factor tyrosine kinase,in symptomatic patients with non-smalll cell lung cancer [J].JAMA,2003,290(16) :2149-2158.
  • 8Sharma S V, Bell D W, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer [J]. Nat Rev Cancer, 2007,7(3) : 169-181.
  • 9林金容 王晓怀 谢波.羟基喜树碱治疗晚期恶性肿瘤的临床研究[J].中国肿瘤临床,2000,27:183-183.
  • 10吴一龙,杨学宁,杨矜记,等.非小细胞肺癌的Gefinitib分子靶向治疗.见:中国临床肿瘤学教育专辑,昆明:云南科技出版社,2004,69—74.

共引文献10

同被引文献13

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部